1. Mitigating neuroinflammation in cognitive areas: exploring the impact of HMG-CoA reductase inhibitor.
- Author
-
Catalão CHR, da Costa LHA, Dos Santos JR, Alberici LC, Falconi-Sobrinho LL, Coimbra NC, Dominguini D, Dal-Pizzol F, Barichello T, and Rocha MJA
- Subjects
- Animals, Rats, Male, Neuroinflammatory Diseases drug therapy, Neuroinflammatory Diseases metabolism, Hippocampus drug effects, Hippocampus metabolism, Prefrontal Cortex metabolism, Prefrontal Cortex drug effects, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Cognition drug effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Rats, Wistar, Sepsis drug therapy, Sepsis metabolism, Simvastatin pharmacology
- Abstract
Existing literature suggests that infection-specific mechanisms may play a significant role in the onset and progression of dementia, as opposed to the broader phenomenon of systemic inflammation. In addition, 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors have been proposed as a potential therapeutic approach for sepsis, given their anti-inflammatory and antioxidant properties. We investigated the neuroprotective effect of an HMG-CoA reductase inhibitor (simvastatin) by analyzing neurodegenerative markers, mitochondrial respiration, and neuronal tracing in the prefrontal cortex (PFC) and thalamic nucleus reuniens (RE) of sepsis survivor animals. Adult Wistar rats were subjected to sepsis by cecal ligation and puncture or left non-manipulated. The animals were treated with simvastatin or vehicle for 4 days before and 10 days after surgery. The treatment preserved the non-associative memory (P < 0.05), recovered expression of Smad-3 in the hippocampus (P < 0.05), and prevented increased expression of calpain-1 (hippocampus: P < 0.0001; PFC: P < 0.05) and GSKβ (hippocampus: P < 0.0001; PFC: P < 0.0001) in the brain structures of the sepsis survivor animals. These animals also showed mitochondrial dysfunction and decreased axon terminals in the RE. Simvastatin seems to restore energy metabolism by improving the electron transfer system (ETS) values in the hippocampus (P < 0.01) and the oxidative phosphorylation/ETS (P/E) ratio in the PFC (P < 0.05), in addition to preventing the reduction of axon terminals in survivor animals. These results suggest a potential neuroprotective effect and the importance of considering HMG-CoA reductase inhibitors as a possible adjuvant therapy in sepsis., (© 2024 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.)
- Published
- 2024
- Full Text
- View/download PDF